FEB 20, 2017 10:31 AM PST
New Precious Metal Attacks Cancer Where it Counts
WRITTEN BY: Xuan Pham
3 51 2277

Researchers have captured how a new organo-metal compound infiltrates cancer cells and destroys its most vulnerable organelle: the mitochondria.

The organo-metal compound, called FY26, is a rare precious metal known as osmium. It was discovered by scientists at the University of Warwick, who previously reported that the metal seemed to shift the metabolism in ovarian cancer cells. In particular, the metal compound stresses cancer cells to use their defective mitochondria, which is a death sentence for these cells.

"Healthy cells generate their energy in organelles called mitochondria, but cancer cells have defective mitochondria and are forced to generate energy through glycolysis in the cytoplasm. Our new compounds work by attacking the energy balance in cancer cells,” explained Dr. Peter Sadler, a professor a the University of Warwick, and the study’s senior author.

In their latest study, Sadler’s team was able to capture just how FY26 targets cancer cells from the inside. They used X-ray fluorescence to track the compound directly to the mitochondria of cancer cells.

"The advanced nano-focussed x-ray beam at ESRF has not only allowed us to locate the site of action of our novel Organo-Osmium FY26 candidate drug in cancer cells at unprecedented resolution, but also study the movement of natural metals such as zinc and calcium in cells. Such studies open up totally new approaches to drug discovery and treatment,” Dr. Sadler said.

In particular, FY26 is reportedly 49 times more potent than Cisplatin - a common platinum-based chemotherapeutic agent.  "Existing platinum-based cancer treatments often become less effective after the first course, as cancer cells learn how they are being attacked, but our new osmium compound with its different mechanism of action, remains active against cancer cells that have become resistant to drugs such as Cisplatin,” said Sadler.

The team also argue that, in addition to the higher potency and selectivity, osmium-based drugs may be cheaper to produce overall. "Cancer drugs with new mechanisms of actions which can combat resistance and have fewer side-effects are urgently needed,” Sadler noted.

Of note, the compound was only tested in ovarian cancer cells and with much higher doses than would be typically used in a clinical setting. As such, further investigations into how FY26 behaves in live animal systems are important to determine if this drug will be appropriate for cancer patients.

Additional sources: MNT

 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 06, 2018
Cancer
APR 06, 2018
PanCancer Atlas of 33 Cancer Types for Genomic Profile Index Completed by NIH TCGA
The Cancer Genome Atlas project used genomic profiles and bioinformatics to catalogue 33 prevalent types of cancer and is available to the public after 10+ years of analysis.
APR 10, 2018
Health & Medicine
APR 10, 2018
Red Meat and Health Risks in Women
Nutrition experts and healthcare providers alike agree that a diet that is limited in red meat is healthier. Lowering intake of red meat can improve heart
APR 10, 2018
Clinical & Molecular DX
APR 10, 2018
New Biomarker Improves Combination Cancer Therapy
Two anti-cancer drugs are better than one, and the discovery of a new biomarker will likely help researchers identify the appropriate timing for the admini
APR 18, 2018
Cancer
APR 18, 2018
Evaluating Perspectives of the Decision-Making Experience for Patients with Cancer and Dementia
A new study evaluated the decision-making experiences for patients with comorbid factors of cancer and dementia from multiple perspectives.
APR 24, 2018
Cancer
APR 24, 2018
Synthetic Retinoid Shows Promise for Inhibition of Cancer Cells
Researchers studied the potential use of a synthetic retinoid, WYC-209, as an inhibitor of cancer cell growth and metastasis via the retinoic acid receptor pathway.
JUL 10, 2018
Cancer
JUL 10, 2018
Risk Allele Variant SNP at 14q11.2 Linked to ALL
Researchers utilized genome-wide association studies to identify a variant SNP within a gene at 14q11.2 which is linked to ALL.
Loading Comments...